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List of abbrevations
5-HT: 5-hydroxytryptamine (serotonin)
aCSF: artificial cerebrospinal fluid
BNST: bed nucleus of stria terminalis
cAMP: cyclic adenosine monophosphate
CNS: central nervous system
CREB: cAMP-responsive element binding protein
DORs: δ opioid receptors
Elk1: Ets-like transcription factor 1
EPM: elevated plus maze
ERK 1/2: extracellular signal-regulated kinase1/2
Ets: E26-AMV virus oncogene cellular homolog, a transcription factor
GHSR-1a: growth hormone secretagogue receptor type 1a
H3: histone 3
KORs: κ opioid receptors
MORs: μ opioid receptors
mRNA: messenger ribonucleic acid
MSK1: Mitogen- and stress-activated kinase 1
NMDA: N-Methyl-D-aspartate
OF: open field
ORL-1: orphan receptor like receptor-1
PACAP: pituitary adenylate cyclase-activating polypeptide
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PENK: proenkephalin
PDYN: prodynorphin
Pol: RNA polymerase II transcription complex
PPE: preproenkephalin
SP: substance P
VIP: vasoactive intestinal polypeptide 
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1 Introduction
1.1 Short historical and clinical overview about morphine
Morphine was originally isolated from opium by German pharmacist Friedrich
Wilhelm Adam Sertürner. In 1806, he published a scientific paper about the results of his
experiments in which he claimed the isolation of “principium somniferum,”  the narcotic
principle of opium. Opium, is the dried latex purified from Papaver somniferum, contains two
main groups of alkaloids: phenanthrenes and isoquinolines. Phenanthrenes such as morphine
(approximately 10-15 % of opium), codeine, and thebaine have effects in the central nervous
system  (CNS);  on  the contrarily, isoquinolines (e.g. papaverine and noscapine) have no
significant actions in the CNS. Morphine was firstly distributed by its inventor in 1817, thus,
morphine-extract is used by humans almost in the past two centuries. Sertürner was the first
who used the name “morphine” in 1817 in one of his publication. This new opium compound
took its name from the Greek god of dreams Morpheus due to its sedative effect. Morphine
was widely used after the perfection of the hypodermic needle in 1857. The next big
breakthrough in morphine research was the discovery of heroin (diacetylmorphine), in 1874,
by Alder Wright. Heroin was given its name due to its “heroic fight”  against pain and
morphine addiction. Heroin was believed to be an effective analgesic opiate without
provoking addiction and also was marketed as a cough suppressant by Bayer in 1898. A few
years later, heroin turned out to cause more severe addiction than morphine, so the production
and distribution of heroin was prohibited in the great majority of the countries. For more
historical details, please see the excellent review of Schiff P. L. Jr., 2002. 
Currently, there are at  least  11 licensed, medical prescription-required morphine-
containing pharmaceutical products available in Hungary  (Online Drug Databese, National
Institute of Pharmacy, 2014). In clinical medicine, morphine is still considered to be the best
analgesic drug used for alleviation of acute and chronic pain (e.g. postoperative pain, please
see reviews: Busch, 1987; Blaudszun et al., 2012). Unfortunately, morphine has a lot of
unwanted side effects especially in chronic treatments, for example tolerance to morphine-
induced analgesia, sedation, reduced euphoria, reduced libido, loss of appetite, etc. After
naloxone-precipitated  morphine withdrawal, these aversive effects become more expressed,
for example hyperalgesia, anxiety, depression, etc. Naloxone is one of the most widely used
9
withdrawal-provoking drug in the clinical practice  and there are 9 licensed naloxone-
containing pharmaceutical products available in Hungary, all of these drugs are medical
prescription-required  (Online Drug Databese, National Institute of Pharmacy, 2014). These
symptoms after withdrawal are  called morphine withdrawal syndrome. Due to extended
human consumption, a lot of studies examined the aversive impacts of morphine treatment
and morphine withdrawal, both in humans and rodents. In spite of intense research there are
still unsolved problems in the clinical pratice (e.g. analgesic tolerance to morphine, undesired
side effects after morphine withdrawal).
1.2 Opioid receptors, opiate peptides, and their role in regulation of pain and anxiety 
in the CNS
1.2.1 Opioid receptor distribution and endogenous opiate peptides
Opiates are the ligands which bind to their specific receptors, the opioid receptors. This
nomenclature was used throughout the Ph.D. thesis. Opiates can be exogenous (e.g. morphine,
codeine, thebaine etc.) or endogenous (see this section). Morphine exerts its effect on specific
G-protein coupled opioid receptors: κ opioid receptors (KORs), μ opioid receptors (MORs), δ
opioid receptors (DORs) (Pert et al., 1973; Pert and Snyder, 1973) and orphan receptor like
receptor-1 (ORL-1( (Mollereaua et al., 1994). These receptors have numerous subtypes, for
more details please see review: Snyder, S. H. and Pasternak G. W., 2003. Naturally, these
receptors have endogenous ligands, called endogenous opiate peptides. The firstly discovered
and purified opiate peptide was β-endorphin sourced from human brain (Li et al., 1976); and
the last identified peptides were endomorphin-1 and endomorphin-2 from the bovine brain
(Zadina et al., 1997) and human cortex (Hackler et al., 1997). Up to this point, there are 22
different identified endogenous opiate peptides (please see review: Fichna et al., 2007). 
All of the  opioid receptors are present in the CNS. The following parts of the
introduction section are focusing on studies about experiments using rodent animal models.
KORs, the specific receptors of dynorphins, have been detected in the ventral tegmental area,
substantia nigra, nucleus accumbens, caudate putamen, various hypothalamus, and the
amygdala of the rat and mouse brain (please see review Bruijnzeel, A. W., 2009); and in
various regions in the mouse and rat spinal cord. KOR messenger ribonucleic acids (mRNAs)
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are highly expressed in the locus coeruleus of the mouse brain, whereas only weakly
expressed in this region of the rat brain. MORs, the specific receptors of endomorphins,
casomorphins, etc., were detected in the cerebral cortex at a low level (only in layer VI), in
the amygdala, in the thalamic nuclei, in the medial raphe nucleus. Intense expression of MOR
mRNAs were detected in the rat and mouse spinal cord lumbar dorsal horn, and moderate
expression in the lumbar ventral horn. DORs, the specific receptors of enkephalins and
deltorphins, were observed in the cerebral cortex (layers II, III, V and VI), little or no
detectable expressions in globus-, ventral pallidum and in the thalamic nuclei in the mouse
brain. High DOR mRNAs expression were detected in the mouse entopeduncular nucleus, and
moderate DOR mRNAs present were observed throughout the laminae I-VI of the mouse
spinal dorsal horn (please see review: Minami and Satoh, 1995). KORs, MORs and DORs are
co-expressed in many regions of the CNS of rodents. 
ORL-1, the specific receptor of nociceptin/orphanin FQ, is highly expressed in the
cortex (layers II to VI), the anterior olfactory nuclei, the dentate gyrus of the hippocampus,
the amygdala, the bed nucleus of the stria terminalis, the substantia nigra, the ventral
tegmental area in the mouse and rat brain. In the rat spinal cord this receptor is also expressed:
in the cell bodies of rat dorsal root ganglia, in the ventral horn (laminae VIII-IX), in the
interneurons of the dorsal horn (see review Mollereau et al, 2000). In the mouse spinal cord,
ORL-1 is identified in the superficial layers of the dorsal horn and around the central canal
(Narita et al., 1999).
1.2.2 The effects of opiates on pain
Endogenous opiate peptides are natural analgesic “drugs” of the central and peripheral
nervous system. All type of opioid receptor mediates analgesia. Morphine can bind to MORs,
DORs and KORs, but morphine exerts its highest analgesic effect through the activation of
the MORs (Matthes et al., 1996).  Endogenous and exogenous opiates can inhibit pain both in
spinal and supraspinal level. 
At spinal level, opiates have presynaptic inhibitory effect on excitatory transmission in
superficial dorsal horn in rodents. Opiates inhibit the release of pronociceptive
neurotransmitters in the spinal cord via prevention of Ca2+ influx.  The most important
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consequence of this prevention is the suppression of substance P (SP) release from primary
sensory neurons, because there is no nociceptive information transmission without SP release
in the spinal cord. At the postsynaptic membrane, opioids evoke hyperpolarization by opening
K+ channels, thereby preventing excitation or propagation of action potentials in second order
projection neurons. In addition, opioids inhibit sensory neuron-specific tetrodotoxin-resistant
Na+ channels and excitatory postsynaptic currents evoked by glutamate receptors, for example
N-Methyl-D-aspartate (NMDA) receptors in the spinal cord (please see review: Stein, 2013).
Endomorphin 2 can act on MORs directly to induce antinociception in the spinal cord,
or (at supraspinal level) enhance the release of Met-enkephalin, dynorphin-A, etc via
descending inhibitory pathways. Noradrenaline and 5-hydroxytryptamine (5-HT) are the most
important neurotransmitters which are involved in descending inhibition. Two important areas
of the brainstem are involved in reducing pain: the periaquaductal grey and the nucleus raphe
magnus  (see  review:  Steeds,  2013).  Endomorphin 1 also affects directly on MORs, or
enhances the release of noradrenalin and serotonin. Thus, endogoneous opiates have very
complex effects on physiological antinociception system (please see review: Fichna et al.,
2007).
There are several behavioral methods for analyzing analgesic actions of morphine in
rodents. For example, tail-flick, hot-plate, etc. for measuring thermal-; Randall Selitto test,
rodent pincher test, etc. for measuring mechanical-; and formalin test, capsaicin test for
measuring chemical nociceptive agents induced behavior.
Morphine has analgesic effect both in mice and rats. There are lots of studies which
demonstrated the development of analgesic tolerance to morphine in mice (Ninan and
Kulkarni, 2000; Mamiya et al., 2001; Contet et al., 2008; etc.) and rats (e.g. Advokat et al.,
1987; Rawls et al., 2010; Ranjbar-Slamloo et al., 2012) using behavioral methods. For more
experimental details, see section 1.2.3.
1.2.3 The role of neuropeptides in morphine-induced behavioral changes 
In the past four decades, the role of endogenous neuropeptides in morphine-induced
behavioral changes was examined by  our Department. These investigations focused on the
effects of the natriuretic peptide family and (vasoactive intestinal polypeptide) VIP family on
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morphine-evoked  behavioral  responses,  especially  on  morphine-induced  analgesia  and
morphine  withdrawal.  Brain  natriuretic  peptide  and  C-type  natriuretic  peptide  are  the
members  of  the  natriuretic  peptide  family.  C-type  natriuretic  peptide  depressed  the  acute
analgesic  effect  of  morphine,  blocked  the  development  of  acute  tolerance  to  morphine
(Babarczy et al., 1995). Brain natriuretic peptide also decreased the acute analgesic effect of
morphine (Babarczy et al., 1996).
VIP decreased the analgesic effect of single injection of morphine and the develop-
ment of chronic tolerance to morphine (Mácsai et al., 1998).  PACAP blocked the nalgesic ef-
fect of acute morphine and enhanced the analgesic tolerance to morphine (Mácsai et al.,
2002). Moreover, PACAP significantly enhanced the naloxone precipitated withdrawal jump-
ing.
1.2.4 The effects of opiates on anxiety
MORs mediates respiratory depression, sedation, reward/euphoria, nausea, urinary
retention and constipation. KORs have dysphoric, aversive, sedative and diuretic effects.
DORs have effect on reward/euphoria, respiratory depression and constipation.  The
regulation of anxiety is a complex system in rodents. The areas of the limbic system (included
the hippocampus, amygdala, anterior thalamic nucleus, septum, prefrontal cortex and the
fornix) have a key role in the modulation of anxiety. Principally, the GABA-A, 5-HT,
cholecystokinin, nor-adrenalin, neuropeptide Y neurotransmitter systems are responsible for
regulation of anxiety and stress-response.
There are numerous behavioral tests for measuring anxiety-like behavior in rodents.
These tests may divide into five types: 
 exploratory behavior tests (e.g. elevated plus maze (EPM), open-field (OF),
light-dark box, etc.);
  social behavior tests;
  reflexive fear tests (e.g. acoustic startle test, conditioned freezing test, etc.); 
 conflict tests (e.g. Vogel conflict test, four-plate test, etc.);
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 defensive behavior tests (e.g. shock-probe burying test, marble burying test,
etc.).
 For more details, see review (Rotzinger et al., 2010). 
Endomorphin 1 decreases the normal preference for the closed arms on EPM in mice
(Asakawa et al., 1998); this is the only one report measuring the effect of endomorphins on
anxiety in rodents. The role of KORs/dynorphin system in anxiety is not clearly understood;
contradictory studies were published in this issue (please see review: Schwarzer, 2009).
Activation of DORs reduces anxiety-like behavior in the central amygdala in rats (Randall-
Thompson et al., 2010). 
Morphine has anxiolytic action in rats injected peripherally (Koks et al., 1999) and
centrally (Motta et al., 1995). Naloxone-precipitated morphine withdrawal has a clear
anxiogenic effect in rats (Schulteis et al., 1998; Zhang and Schulteis, 2008). Repeated
subcutaneous morphine administration in increasing doses also evokes anxiety-like behavior
in mice (Hodgson et al., 2008). Furthermore, both naloxone-precipitated (Hodgson et al.,
2008) and spontaneous morphine withdrawal (Buckman et al., 2009) caused increased
elevated plus maze open-arm time in mice. This elevated plus maze behavior was blocked by
SL327 (a selective ERK 1/2 inhibitor) after its injection into the amygdala (Hofford et al.,
2009) indicating the role of ERK 1/2 in this unexpected behavior of mice. 
 
1.2.5 Intracellular changes evoked by acute and chronic morphine treatment in the 
CNS in rodents 
All type of opioid receptors couple to G-proteins and subsequently inhibit adenylate
cyclase in the presence of an  agonist. Thus, acute morphine administration  reduces
intracellular cAMP level (Sharma et al., 1975); decrease the conductance of voltage-gated
Ca2+ channels and open rectifying K+ channels. Furthermore, acute morphine treatment causes
a rapid and transient increase extracellular signal-regulated kinase (ERK) phosphorylation in
the nucleus accumbens (NAcc), central amygdala, prefrontal cortex, lateral bed nucleus of
stria terminalis (BNST) in mice (Valjent et al., 2004). Acute single morphine injection does
not change the proenkephalin (PENK) and prodynorphin (PDYN) mRNA level in the nucleus
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accumbens or striatum (Turchan et al., 1997) in mice. On the other hand, acute intermittent
morphine treatment increases the preprodynorphin and KOR mRNA levels, but does not alter
preproenkephalin (PPE) mRNA level in the rat cortex and cerebellum (Wang et al., 1999).
One of the first consequences of chronic morphine treatment is the opioid receptor
endocytosis (please see review of von Zastrow et al., 2003) and desensitization of opioid
receptors. Desensitization is a progressive loss of receptor function under continued exposure
to opiate agonists  (Murányi et al., 2013). Opioid receptors desensitizatied by the G-protein
coupled receptor kinases and second messenger regulated protein kinases (Polakiewicz et al.,
1998). Desensitization and endocytosis may play an important role in the early stages of
analgesic tolerance to morphine and morphine dependence. In contrast to acute treatment,
chronic exposure to morphine causes a gradual loss in the opioid-mediated adenylate cyclase
inhibition and a marked increase in adenylate cyclase activity (Nevo et al., 1998). This
phenomenon called adenylate cyclase super activation and is supposed to participate in the
development of morphine tolerance and dependence but the underlying mechanism of this
super activation has not been clarified yet. This increased cAMP level (which was increased
directly via opioid receptors or indirectly via D1 dopamine receptors) induces a marked
elevation in ERK 1/2 phosphorylation during morphine dependence. After naloxone
precipitated withdrawal, this elevation becomes more expressed both in mice and rats (Li et
al., 2010). ERK2 can enter into the nucleus and regulates transcription of mRNAs of cFos,
dynorphin, etc. via phosphorylation of mitogen- and stress-activated kinase 1 (see Figure 1).
Repeated morphine administration reduces the PENK mRNA level in the nucleus accumbens
and in the striatum, but elevates the PDYN mRNA level in both those structures in mice
(Turchan et al., 1997). Withdrawal from chronic morphine treatment also causes increased
PPE mRNA level in rat periaqueductal gray (Fukunaga et al., 1998). These elevations may be
regulated via increased ERK 1/2 phosphorylation (Ji et al., 2002).
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Figure 1:  The Regulation of transcription by ERK2 in the mice striatum. Figure
adapted from: Girault et al., 2007.
ERK 1/2 is activated by almost all of drug of abuse (e. g. cocaine, nicotine, morphine,
tetrahydrocannabinol), therefore ERK 1/2 phosphorylation might be the common “step” in the
development of drug-induced plasticity and addiction (for more details please see review:
Girault et al., 2007).
1.2.6 PACAP
PACAP was originally isolated from ovine hypothalamus by its potent activity in
stimulating cAMP production in rat anterior pituitary cells (Arimura, 1992). PACAP is a
neuropeptide and member of a VIP superfamily that includes numerous peptides, e.g. VIP,
secretin, helodermin, glucagon, galanin, etc. (Christophe, 1993; Gourlet et al., 1998). PACAP
has two amidated forms: PACAP-38 and PACAP-27 (Miyata et al., 1990). The presence of
PACAP was detected in hypothalamus, medial and ventral areas of the diencephalon, central
thalamic nuclei, amygdala, BNST, septum, hippocampus, cingulate and entorhinal cortex,
substantia nigra, nucleus accumbens, globus pallidus and sacral spinal cord (Dietl et al.,
1990; Joo et al., 2004). Two receptor classes were described for PACAP in mammalian
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tissues: type I and type II. Type II was further divided into three subclasses: PAC1, VPAC1
and VPAC2. PAC1 receptors are more selective for PACAP than VIP, but VPAC1 and VPAC2
receptors show similar affinity for PACAP-27, PACAP-38 and VIP (Cauvin et al., 1990;
Gourlet et al., 1996). Type I receptors stimulate both adenylate cyclase and phospholipase C,
thus being coupled to dual transduction pathways, involving interactions with G proteins of
both Gs- and Gq-type. PACAP-38 and PACAP-27 were also effective in increasing cAMP
release, cellular cAMP content, and total cAMP production in a dose-dependent in rat
neuroepithelial cells (Zhou et al., 2001). Behavioral studies examined the PACAP effect on
motor stimulation and conditioned place preference (CPP) induced by morphine (Marquez et
al., 2009); analgesic tolerance to morphine (Mácsai et al., 2002); mechanical hyperalgesia
and thermal allodynia (Sándor et al., 2010). Earlier experiments done by our research group
demonstrated that PACAP diminished the antinociceptive effect of acute morphine and
enhanced the analgesic tolerance to morphine pellet (Mácsai et al., 2002). Low doses of
PACAP (0.03 and 0.3 μg), which had no effect on basal motor activity, enhanced morphine-
induced (5 mg/kg, s.c.) motor stimulation and PACAP-deficient mice exhibited reduced
morphine-induced motor stimulation (Marquez et al., 2009). Morphine-induced CPP
following a single alternate-day saline/morphine (10 mg/kg, s.c.) conditioning was blunted in
PACAP-deficient mice compared to their wild type littermates (Marquez et al., 2009). 
1.2.7 Ghrelin and obestatin
Obestatin and ghrelin belong to the same neuropeptide family. Ghrelin, a 28-amino acid
peptide, was isolated from rat stomach and identified as an endogenous ligand for (growth
hormone secretagogue receptor type 1a) GHSR-1a (Kojima et al., 1999). Ghrelin and GHSR-
1a mRNA was detected in peripheral organs (e.g. stomach, lung, heart, kidneys, etc.), and in
the central nervous system. GHSR-1a was identified in rodent hypothalamus, pons, medulla
oblongata,  cortex,  midbrain  and spinal  cord  (Zigman et  al.,  2006;  Vergano et  al.,  2008).
Ghrelin immunoreactive neurons in the hypothalamus densely innervate proopiomelanocortin
neurons (Cowley et al., 2003); suggesting that ghrelin can regulate the release of β-endorphin
and the analgesic effect of endogenous opiates. Interestingly, peptides encoded by the ghrelin
gene (acylated ghrelin,  unacylated  ghrelin and obestatin)  can activate  extracellular  signal-
related kinase 1/2 human pancreatic islet endothelial cells (Favaro et al., 2012). Furthermore,
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[D-Lys3]-GHRP-6 blocked the obestatin-induced cell survival in human pancreatic islet cells
(Granata  et  al.,  2008);  hence  GHSR-1a  may  participate  in  the  physiological  effects  of
obestatin.  Ghrelin  can  prevent  mechanical  hyperalgesia  (Garcia  et  al.,  2008)  and
inflammatory pain (Sibilia et al., 2006).  In addition, a very recent study has claimed that
ghrelin can induce a dose- and time-dependent analgesic effect in the acute heat-induced pain
in mice (Wei et al., 2013). This effect of ghrelin was significantly antagonized by [D-Lys3]-
GHRP-6, a specific  GHS-R1a antagonist,  and by naloxone,  indicating  the involvement  of
endogenous opioid system in the analgesic effect of ghrelin (Wei et al., 2013). The role of
ghrelin in reward (please see reviews in this issue: (Dickson el at., 2011; Skibicka and
Dickson, 2011) and in anxiety (Andrews et al., 2011) are well-examined research areas, but
the role of obestatin in these research fields has not been clarified yet.
Obestatin, a ghrelin-associated peptide derived from the preproghrelin was discovered
by Zhang et al., 2005. Obestatin was purified from the rat stomach and was initially reported
to reduce food intake, gastric emptying and intestinal motility (Zhang et al., 2005; Bresciani
et al., 2006). It was also characterized as an activator of the orphan G protein-coupled GPR39
receptor and was found to be the main ligand for it. The highest levels of GPR39 mRNA were
detected by in situ hybridization in the amygdala, the hippocampus, and the auditory cortex,
while lower levels were found in several other brain regions but surprisingly no expression of
GPR39 was found in the hypothalamus in mice (Jackson et al., 2006). GPR39 receptor has
two splice variants, GPR39-1a and GPR39-1b. GPR39-1a is expressed selectively in the
gastrointestinal tract, whereas GPR39-1b has a wider expression pattern, including nuclei in
the central nervous system, for example the amygdala, and hippocampus (Egerod et al.,
2007). Later studies reported that GPR39 may not have obestatin as a main ligand (Chartrel
et al., 2007; Holst et al., 2007; Lauwers et al., 2007). After these findings, Zhang et al.
confirmed that their original result was unreproducible (Zhang et., 2007) and subsequent
results suggested that glucagon-like peptide-1 receptor (GLP-1R) is the receptor of obestatin
(Granata et al., 2008; Favaro et al., 2012). Moreover, a few in vitro studies claimed that
obestatin stimulated ERK1/2 phosphorylation, in rat tumor somatotroph cells (Pazos et al.,
2009); in human pancreatic islet cells (Favaro et al., 2012;  Granata et al., 2008) and in
human retinal pigment epithelial cells (Camiña et al., 2007). In the past few years metabolic
and body weight-regulating effect of obestatin has been investigated in detail, however, there
are only a few reports, which examined the role of obestatin in exploratory behavior and its
analgesic effect. A previous study on the EPM indicated that obestatin induced elevation of
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the %OAT and %OAE in rat (Carlini et al., 2007). These data were later confirmed by
Ishitobi et al., 2012: intracerebroventricular administration of antisense DNA for GPR39-1b
caused anxiolytic-like effect in rats in two different behavioral tests. The same research group
discovered that ghrelin decreased the %OAT in the EPM and increased the ambulation time in
the OF test in rats and neonatal chicks (Carlini et al., 2002; Carvajal et al., 2009). 
1.3 Aims
The aims of the current works were the following points:
 to examine the effects of PACAP on naloxone precipitated morphine withdrawal using EPM 
and withdrawal jumping test.
 to analyze the effects of obestatin on naloxone precipitated morphine withdrawal using EPM 
and open-field test.
 to investigate the actions of obestatin on morphine-induced acute tolerance and analgesic 
tolerance to morphine using the tail-flick test.
2 Materials and methods
2.1 Animals
Male CFLP white mice (30 ± 5 g of weight) of an outbred strain (Domaszék, Hungary)
were used. They were kept under a standard light–dark cycle (lights on between 07.00 and
19.00 h) with food and water available ad libitum. The animals were kept and treated
according to the rules of the Ethical Committee for the Protection of Animals in Research
(Faculty of Medicine, University of Szeged, Hungary).
2.2 Surgery
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For intracerebroventricular (i.c.v.) cannulation, the mice were anesthetized with
intraperitoneal (i.p.) injection of sodium pentobarbital (Nembutal, Phylaxia-Sanofi, Budapest,
Hungary; 50 mg/ kg or EuthasolR, Produlab Pharma B.V. Raamsdonksveer, The Netherlands;
60 mg/kg), and a polyethylene cannula was inserted into the right lateral cerebral ventricle
and cemented to the skull with cyanoacrylatecontaining instant glue. The experiments were
started 4 days after i.c.v. cannulation. Upon conclusion of the experiments, methylene blue
was injected into the cerebral ventricle of the decapitated animals and the position of the
cannula was inspected visually. Mice with improper cannula placement were excluded from
the statistical analysis.
2.3 Drugs
For i.c.v. treatments, PACAP-38 (syntethized by Gábor Tóth), obestatin 1-23 (Anaspec,
Inc., USA) and [D-Lys3]-GHRP-6, (Sigma Aldrich, USA) were dissolved in aCSF and
injected in a volume of 2 μl. For testing the morphine effects, subcutaneous (s.c.) morphine-
HCl (Sigma-Aldrich) and naloxone-HCl (Sigma-Aldrich) injections were used. 
2.4 Assesment of naloxone-precipitated withdrawal jumping in mice treated graded 
doses of morphine
Precipitated withdrawal jumping latency was measured in mice treated with morphine
in the presence and absence of PACAP after naloxone (1 mg/kg, s.c.) administration.
Immediately after naloxone or saline injection, mice were placed on a circular platform. The
precipitated abstinence syndrome was measured by scoring the latency to the apperance of
stereotyped jumping from a circular platform 35 cm indiameter and 70 cm high (Azarov et al.,
1992) . A cut off time of 15 min was used. The rectal body temperatures and body weights of
all animals were also measured 15, 30, 60 min after naloxone injection, and changes in both
parameters were calculated.
2.4.1 Influence of PACAP on naloxone-precipitated morphine withdrawal symptoms
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We used twice daily injections (09.00 and 19.00 h.)  of  graded  doses  of  morphine as
follows: day 1: 20 mg/kg, day 2: 40 mg/kg, day  3:  60 mg/kg,  day  4:  80 mg/kg  or  saline
(Contet  et  al.,  2008). Mice were also treated once a day (09.30 h) with either PACAP (500
ng/2 μl) or aCSF i.c.v. On the test day (day 5) animals received in the morning a single
morphine injection (100 mg/kg s.c., 9.00 h) or saline (s.c.). Ninety minutes later aCSF or
PACAP was given (10.30 h, i.c.v.). Withdrawal signs were evoked by naloxone administration
(1 mg/kg, s.c.) 2 h after the ﬁnal morphine treatment. Precipitated  morphine  withdrawal
syndrome  was  induced  by 1 mg/kg  naloxone-HCl  as  described  by Azarov  et  al., 1992.
For specific groups and treatments see section 3.1.
2.5 Elevated plus maze
The EPM is an accepted model for examining anxiety-like behavior in mice (Lister,
1987). Conditions that decrease time spent in the open arms are associated with anxiety-like
behavior, whereas increased time spent in the open arms is associated with an anxiolytic
effect. The EPM apparatus (Columbus Instruments, Columbus, Ohio, USA)consists of four
arms  (87-mm  wide,  155-mm  long)  elevated  63.8 cm  above  the ground,  with  two  arms
enclosed  by  16.3-cm-high  opaque  walls and  illuminated  with  60 W light situated 1 m
above the maze. The combination of height, luminosity and open space is assumed to induce
anxiety-like behavior in the animal.  Behavioral testing was conducted between 11.00 and
13.00 h.  Mice were carried to the experimental room in their homecages and habituated to the
laboratory for at least 30 min before testing. Only one EPM apparatus per testing room was
present. The apparatus was thoroughly cleaned between mice. Mice were placed in the center
of the maze facing toward an enclosed arm and there behavioral activity was recorded for 10
min (Schulteis et al., 1998). The following behavioral parameters were monitored: the time
spent in open arms and the entries into open arms compared to the total time (%OAT) and
entries  (%OAE) and  the  total  activity  which  was  defined  as  the  total  number  of  crosses
between any two arms.
2.5.1 The effects of PACAP on EPM behavior
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Mice were treated once a day (09.30 h) with either PACAP (500 ng or 1 μg i.c.v. or
aCSF for 3 consecutive days. On the test day (day 4) PACAP or aCSF was administered 30
min before EPM assessment. The parameters were monitored as mentioned above.
2.5.2 The effect of naloxone on EPM behavior in mice treated with morphine 
 We used twice daily injections (09.00 and 17.00 h.) of graded doses of morphine as
follows: day 1: 10 mg/kg, day 2:  20 mg/kg, day 3: 40 mg/kg or saline (Hodgson et al., 2008).
On the test day (day 4) animals received a single dose of morphine (20 mg/kg, s.c.) or saline
(s.c.) in the morning at 09.00 h. Naloxone treatment in a dose of 0.1 mg/kg, or 0.2 mg/kg, s.c.
Preceded behavioral    assessment      by 5 min.   The   behavioral     changes    were measured
2 h  after  the  ﬁnal  morphine  treatment  with  EPM  test (Higgins and Sellers, 1994;
Schulteis  et  al.,  1994).  For treatment schedule, see section 3.1.
2.5.3 The effect of naloxone and PACAP on EPM behavior in mice treated with 
morphine 
Morphine administration regimen was the same as in 2.5.2. In addition, mice were
treated once a day with either PACAP (500 ng/2 μl) or aCSF (i.c.v.) at 09.30 h. On the test
day (day 4) animals received the ﬁnal morphine dose (20 mg/kg) s.c.), or saline (s.c.). 9.00 h
and either aCSF or PACAP (i.c.v.) was given at 10.30 h. Naloxone  treatment  and  behavioral
assessment were conducted in the same way as outlined in the 2.5.2 with one exception that
only  the  higher dose of naloxone was used (0.2 mg/kg, s.c.).  For treatment schedule, see
section 3.3.
2.5.4 The effect of naloxone and obestatin on EPM behavior in mice treated with 
morphine
                                                                                        
Morphine (08.00 and 16.00 h) and naloxone administration regimen was the same as
in 2.5.3. In addition, mice were treated once a day with either obestatin (1.5 μg/2 μl) or aCSF
(i.c.v.) at 08.15 h. On the test day (day 4) animals received a single dose of morphine (20
mg/kg, s.c.) or saline (s.c.) at 08.00 h and either aCSF or obestatin (i.c.v.) was given at 09.45
h.  For specific groups and treatments see section 3.5.
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2.6 Open field 
Obestatin effects on mild morphine withdrawal were also tested by the Conducta System
(Experimetria Ltd., Budapest, Hungary). The apparatus consists of five black-painted testing
boxes  (40cm×50cm×50cm  each)  set  in  an  isolated  room;  the  movements  of  mice  were
detected by high-density arrays of infrared diodes. One animal was placed in one box, the
apparatus is able to test 5 mice at the same time and there is no connection between them. The
floor of the box was washed with ethanol (96%), water and dried prior to the next animal
testing. On test day, mice were transported to the testing room and  the percentage of time
spent in the center and ambulation distances in the center were recorded individually for each
animal and separately for each box.
2.6.1  The effect of graded doses of acute obestatin on OF behavior in mice
Obestatin was administrated i.c.v. at graded doses: 0.5 - 2 μg. Mice were tested 15 min
after the obestatin treatment for 10 minutes. 
2.6.2  The effect of naloxone on OF behaviors in mice treated with obestatin
We used twice daily injections of saline. Mice were also treated once a day with either
obestatin (1.5 μg/2 μl, i.c.v., respectively) or aCSF (i.c.v.) at 08.15 h. On the test day (day 4)
animals received saline (s.c.) at 08.00 h and either aCSF or obestatin (i.c.v.) was given at
09.45 h. Naloxone treatment in a dose of 0.2 mg/kg, s.c. preceded behavioral assessment by 5
min. The behavioral changes were measured 2 h after the final saline treatment in the OF.
2.6.3 The effect of naloxone and obestatin on OF behavior in mice treated with 
morphine
Treatment protocol was the same as in 2.5.4.  For specific groups and treatments see
section 3.5.
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2.7 Tail-flick
Obestatin effect on morphine-evoked analgesic response tested by the tail-flick system
(IITC  Life  Science,  California,  USA)  described  by  D’Amour  and  Smith,  1941.  All
experiments were started with an initial tail-flick latency measurement, pain sensitivity was
measured 15, 30, 60 min after peptide challenge in acute dose-response experiments and 60,
90, 120 min after morphine treatment  in acute morphine experiment  (day 1). In tolerance
studies,  pain  sensitivity  was  measured  60  min  after  morphine  injection.  For  tail-flick
measurement,  animals  were habituated  to the experimental  room at  least  30 min  prior  to
testing. During the measurement, they were loosely restrained and the tail was positioned so
that the light beam focused on the tail approximately 1–2 cm from the base. Tail stimulation
was  delivered  at  different  sites  in  consecutive  measures  to  prevent  tissue  damage.  The
analgesic effect was expressed according to this equation:
analgesic effect (%) = (TFn – TF0)/ (TFmax - TF0) x 100,
where  TF0 is  the  tail-flick  latency  in  the  preliminary  test  mentioned  above  or  (in
tolerance studies) before morphine injection. TFn is the value of a repeated corresponding
measurement n (15, 30, 60 or 60, 90, 120 min) after obestatin or/and morphine injection, and
TFmax indicates the cutoff (20 s). 
2.7.1   The analgesic effect of graded doses of acute obestatin
Obestatin was administrated i.c.v. at graded doses: 0.5 - 2 μg. Mice were tested 15, 30
and 60 min after the obestatin treatment. 
2.7.2 The effect of obestatin on analgesic effect induced by acute morphine treatment 
(1st day)
Mice were treated 10 mg/kg morphine (s.c.) or saline (s.c.) at 09.00 h, an hour before to
first tail-flick measurement. Obestatin or aCSF were injected i.c.v. at 09.45 h. The analgesic
response  was  measured  60,  90  and  120  min  after  the  morphine  injection.  For  treatment
schedule see section 3.9.
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2.7.3 The effect of obestatin on analgesic tolerance to morphine
To develop morphine tolerance, mice received either morphine (10 mg/kg, s.c.) or saline
twice daily for four days, at 09.00 and 16.00  (Mamiya et al, 2011). Mice also treated with
either obestatin or aCSF once a day at 09.45 h. On the fifth day, morphine was administrated
only in the morning at 09.00 h. Obestatin treatment was the same as previous days. Analgesic
effect was measured on the 1st, 3rd and 5th days in the morning at 10.00 h.  For treatment
schedule see section 3.10.
2.8 Statistical analysis
Statistical analysis of the elevated plus maze, open-field and jump test data was made by one-
way analysis  of  variance  (ANOVA) followed  by Sidak or  Tukey post-hoc  test.  Tail-flick
experiments  were analyzed using two-way repeated measures  ANOVA, where drug effect
(between subjects),  time effect  (within subjects)  and their  interactions  were analyzed.   In
presence of interactions between drug and time, drug differences depend on time and vice
versa, so in case of significant interaction drug effects were tested on each time point and time
differences were tested in each group by Sidak post-hoc test. A probability value, P < 0.05
was considered statistically significant. The numbers in parentheses indicate the number of
mice per group.
3 Results
3.1  Influence of PACAP on naloxone-precipitated morphine withdrawal symptoms
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Repeated treatment of PACAP shortened jump latency in mice treated   with   morphine
and   challenged    with    naloxone    [F(3,37) = 23,73, P < 0,023] (Fig. 2). (Tukey post-hoc)
Figure 2. The effect of PACAP on naloxone-precipitated withdrawal jumping in mice
treated with graded doses of morphine. Bars represent the latency of jump, vertical lines on
the top of the bars denote S.E.M., *: p < 0.05 vs. morphine withdrawal mice. 
Mice received the following treatments:
 Control mice: Twice daily injections of saline (Sal), s.c. (09.00 and 19.00
h.) and once daily injection aCSF, i.c.v. (09.30.) for 4 consecutive days.
On the test day, mice given: Sal, s.c. (09.00 h), aCSF, i.c.v. (10.30 h) and
Sal,  s.c. (11.00 h).
 Morphine withdrawal mice:  Twice daily injections of graded doses of
morphine (Mor), s.c. (09.00 and 19.00 h.) and once daily injection aCSF
(09.30.), i.c.v., s.c. for 4  consecutive days. On the test day, mice given:
Mor, s.c. (09.00 h), aCSF. i.c.v. (10.30 h.), and Sal, s.c., (11.00 h).
 Morphine withdrawal mice + PACAP: Twice daily injections of graded
doses of Mor, s.c. (09.00 and 19.00 h.) and once daily injection PACAP
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(09.30.), i.c.v., s.c. for 4  consecutive days. On the test day, mice given:
Mor, s.c. (09.00 h), PACAP (i.c.v.), and naloxone (Nal) s.c., (11.00 h).
 Mice treated with PACAP: Twice daily injections of Sal, s.c. (09.00 and
19.00 h) and once daily injection PACAP, i.c.v. (09.30.) for 4 consecutive
days.  On  the  test  day,  mice  given:  Sal,  s.c.  (09.00  h),  PACAP, i.c.v.
(10.30 h) and Sal, s.c. (11.00 h).
Fifteen   minutes     after   naloxone     treatment     PACAP     blunted hypothermia
induced     by   morphine     withdrawal      [F(3,37) = 32,97, P < 0,034].  However, 30 and 60
min after withdrawal PACAP had no signiﬁcant effect on body temperature (Fig. 3). (Tukey
post-hoc)
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Figure 3.  The effect of PACAP on hypothermia induced by naloxone in mice treated
with morphine. Bars represent the decreasing of body temperature, vertical lines on the top of
the  bars  denote  S.E.M.,  *:  p  <  0.05  vs.  mice  given  morphine  and  naloxone.  Treatment
schedule was the same as was described under Figure 2. 
PACAP treatment alone did not inﬂuence the body weight of mice upon withdrawal
(data not shown). 
3.2 The effects of PACAP on EPM behavior
Both doses of PACAP increased the %OAT, but no signiﬁcant difference was observed.
There was a slight increase upon the higher dose of PACAP compared to control mice [F(2,27) =
3.63,  P < 0,0614].   PACAP had no effect on total activity (data not shown).
3.3 The effect of naloxone on EPM behavior in mice treated with morphine 
Naloxone (0.2 mg/kg, s.c.) administration in mice treated with morphine significantly
increased the %OAT compared to the control mice and mice treated with morphine [F(3,42) =
3,97, P < 0,0146]. Naloxone also significantly enhanced the %OAE compared to the control
mice and mice receiving 0.1 mg/kg naloxone [F(3,42) = 4,18, P < 0,0117]. Naloxone (0.1 mg/kg,
s.c.)  had no significant  effect  on withdrawal  behavior  compared to the  mice  treated  with
morphine (Fig. 4). (Tukey post-hoc)
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Figure 4.  The effect of naloxone on EPM behavior in mice treated with morphine.  Bars
represent the open-arm time/total time rate and the number of open arm entries/total entries
rate, vertical lines on the top of the bars denote S.E.M., *: p < 0.05 vs. control mice and mice
treated with morphine. 
Mice received the following treatments:
 Control mice: Twice daily injections of Sal, s.c. (09.00 and 17.00 h.) for
3 consecutive days. On the test day, mice given: Sal, s.c. (09.00 h) and
Sal, s.c. (10.55 h).
 Mice treated with morphine: Twice daily injections of graded doses of
Mor, s.c. (09.00 and 17.00 h.) for 3  consecutive days. On the test day,
mice given: Mor, s.c. (09.00 h) and Sal, s.c., (10.55 h).
 Morphine withdrawal mice (Nal 0,1 mg/kg):  Twice daily injections of
graded doses of Mor, s.c. (09.00 and 17.00 h.) for 3 consecutive days. On
the test day, mice given: Mor, s.c. (09.00 h) and Nal, s.c., (10.55 h).
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 Morphine withdrawal mice (Nal 0,2 mg/kg):  Twice daily injections of
graded doses of Mor, s.c. (09.00 and 17.00 h.) for 3 consecutive days. On
the test day, mice given: Mor, s.c. (09.00 h) and Nal, s.c., (10.55 h).
3.4 The  effect  of  naloxone  and  PACAP on  EPM  behavior  in  mice  treated  with
morphine 
In combination with PACAP (for treatment details see Table 3), naloxone administration
in mice treated with morphine again significantly increased  %OAT compared to the control
mice and mice treated with morphine [F(3,35) = 5,32, P < 0,0037]. However, PACAP had no
significant effect on EPM compared to morphine withdrawal group (Figure 6). (Tukey post-
hoc)
Figure 5.  The effect of naloxone and PACAP on EPM behavior in mice treated with
morphine. Bars represent the open-arm time/total time rate, vertical lines on the top of the
bars denote S.E.M., *: p < 0.05 vs. control mice and mice treated with morphine. 
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Mice received the following treatments:
 Control mice: Twice daily injections of Sal, s.c. (09.00 and 17.00 h.) and
once daily injection aCSF, i.c.v. (09.30.) for 3 consecutive days. On the
test day, mice given: Sal, s.c. (09.00 h), aCSF, i.c.v. (10.30 h) and Sal,
s.c. (10.55 h).
 Mice treated with morphine: Twice daily injections of graded doses of
Mor, s.c. (09.00 and 17.00 h.) and once daily injection aCSF (09.30.),
i.c.v. for 3 consecutive days. On the test day, mice given: Mor, s.c. (09.00
h), aCSF. i.c.v. (10.30 h.), and Sal, s.c., (10.55 h).
 Morphine withdrawal mice:  Twice daily injections of graded doses of
Mor, s.c. (09.00 and 17.00 h.) and once daily injection aCSF (09.30.),
i.c.v. for 3 consecutive days. On the test day, mice given: Mor, s.c. (09.00
h), aCSF, i.c.v. (10.30 h.), and Sal, s.c., (10.55. h).
 Morphine withdrawal mice + PACAP: Twice daily injections of graded
doses of Mor, s.c. (09.00 and 19.00 h.) and once daily injection PACAP
(09.30.), i.c.v. for 3 consecutive days. On the test day, mice given: Mor,
s.c. (09.00 h), PACAP, i.c.v. (10.30 h.), and Sal, s.c., (10.55. h).
Total motor activity was reduced in mice treated with morphine, a response that was not
altered in mice treated with naloxone. However, PACAP had no significant effect on total
activity compared to morphine withdrawal group (Figure 6). (Tukey post-hoc)
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Figure 6.  Bars represent the total activity; vertical lines on the top of the bars denote
S.E.M. Treatment schedule was the same as was described under Figure 5.
3.5 The effect of naloxone on EPM behaviors in mice treated with obestatin
Obestatin alone had no effect on the EPM behavior compared to control mice. Obestatin
treated mice undergoing withdrawal showed decreased tendency in both parameters (Figure
7A, B) compared to the morphine withdrawal mice that did not receive obestatin,  but the
differences were not significant (%OAT: [F(4,38) =7,11, P < 0,086]; %OAE: [F(4,38) =7,11, P <
0,227].  (Sidak post-hoc)
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Figure 7.  Bars represent the %OAT (Fig. 7A) and the %OAE (Fig. 7B), vertical lines
on  the  top  of  the  bars  denote  S.E.  M.  A *:  p<0.05  vs.  control  mice,  mice  treated  with
morphine and mice treated with obestatin. B *: p<0.05 vs. control mice, mice treated with
morphine and mice treated with obestatin.  Naloxone caused a significant  increase in both
parameters  in  morphine  treated  mice  compared  with  control  mice  and  mice  treated  with
morphine [F(4,38) =11,01, P < 0,002]. 
Mice received the following treatment:
 Control mice: Twice daily injections of Sal, s.c. (08.00 and 16.00 h.) and
once daily injection aCSF, i.c.v. (08.15 h) for 3 consecutive days. On the
test day, mice given: Sal, s.c. (08.00 h), aCSF, i.c.v. (09.45 h) and Sal,
s.c. (9.55 h).
 Mice treated with obestatin: Twice daily injections of Sal, s.c. (08.00 and
16.00 h.)  and  once  daily  injection  obestatin,  i.c.v.  (08.15  h)  for  3
consecutive days.  On  the  test  day,  mice  given:  Sal,  s.c.  (08.00  h),
obestatin, i.c.v. (09.45 h) and Sal, s.c. (9.55 h).
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 Mice treated with morphine: Twice daily injections of graded doses of
Mor, s.c. (08.00 and 16.00 h) and once daily injection aCSF (08.15 h),
i.c.v. for 3 consecutive days. On the test day, mice given: Mor, s.c. (08.00
h), aCSF. i.c.v. (09.45 h and Sal, s.c., (9.55 h).
 Morphine withdrawal mice:  Twice daily injections of graded doses of
Mor, s.c. (08.00 and 16.00 h.) and once daily injection aCSF (08.15 h),
i.c.v. for 3 consecutive days. On the test day, mice given: Mor, s.c. (08.00
h), aCSF, i.c.v. (09.45. h.), and Nal, s.c., (9.55. h).
 Morphine withdrawal mice + obestatin: Twice daily injections of graded
doses of Mor, s.c. (08.00 and 16.00 h) and once daily injection obestatin
(08.15 h), i.c.v. for 3 consecutive days. On the test day, mice given: Mor,
s.c. (08.00 h), obestatin, i.c.v. (09.45. h), and Nal, s.c., (9.55. h).
Figure 8. The effect of naloxone and obestatin on total  activity in mice treated with
morphine. Morphine withdrawal mice receiving obestatin did not show significant changes in
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total  activity  compared  to  morphine  withdrawal  mice  [F(4,38)  =9,243,  P  <  0,682].Bars
represent the total  activity;  vertical  lines on the top of the bars denote S.E. M.  Treatment
schedule was the same as was described under Figure 7.
3.6  The effect of graded doses of acute obestatin on OF behavior in mice
The 1.5 μg/2μl dose of obestatin had a moderate decreasing effect on the percentage of
time spent in the center compared to control mice so this dose of obestatin was selected for
the following experiments (data not shown).
3.7  The effect of naloxone on OF behaviors in mice treated with obestatin
Naloxone  alone  had  no  effect  on  the  percentage  of  time  spent  in  the  center  and
ambulation distance in the center. Mice treated with naloxone and obestatin did not show any
changes in these parameters (data not shown). 
3.8 The effect of naloxone and obestatin on OF behavior in mice treated with 
morphine
Obestatin alone had no significant effect on both parameters compared to control mice.
Obestatin  significantly  decreased  the  percentage  of  time  spent  in  the  center  in  mice
undergoing  naloxone-precipitated  mild  morphine  withdrawal  [F(4,51)=10.998,  P<0,045]
(Figure 9B). Obestatin had no significant effect on the percentage of ambulation distance in
center in mice treated with morphine and naloxone [F(4,51)=13,149,  P<0,998] (Figure 9A).
Naloxone  precipitated  mild  morphine  withdrawal  caused  significant  increase  in  both
parameters compared control mice and mice treated with morphine (the percentage of time
spent in the center:  [F(4,51)=10,998,  P<0,001];  the percentage of ambulation distance in the
center: [F(4,51)=13,149, P<0,005]). (Sidak post-hoc)
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Figure 9. Bars represent the percentage of ambulation distance in the center (Figure
9A) and the percentage of time spent in the center (Figure 9B) vertical lines on the top of the
bars denote S.E. M. Figure 9A *: p<0.05 vs. control mice and mice treated with morphine.
Figure 9B **: p<0.05 vs. control mice, mice treated with morphine and morphine withdrawal
mice receiving obestatin. Treatment schedule was the same as was described under Figure 7.
 
3.9 The effect of obestatin on analgesic effect induced by acute morphine treatment 
(1st day)
Mice treated with morphine showed significant higher pain sensitivity 90 and 120 min
after morphine injection compared to first measurement (60 min) of the same group [F(3,28)=
12.482, P<0,001] and significant lower pain-related behavior compared control in all time of
measurements. Obestatin maintained the analgesic effect of morphine 90 and 120 min after
morphine  injection  in  mice  treated  with  morphine  receiving  obestatin  compared  to  mice
treated with morphine (90 min: [F(3,28)= 6,285,  P<0,01]; 120 min: [F(3,28)= 6,285,  P<0,001].
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Drug - time interactions (drug-time [F(3,28)=7,198,  P<0,001];  time [F(3,28)=7,912,  P<0,003];
drug [F(3,28)=45,175, P<0,003]) were significant (Figure 10). (Sidak post-hoc)
Figure 10.  Curves represent  the  percentage of analgesic  effect;  vertical  lines on the
curves denote S.E. M.  *: p <0.05 vs. mice treated with morphine and control mice at 90th
min; **: p <0.05 vs. mice treated with morphine and control mice at 120th min; #: p <0.05 vs.
mice treated with morphine at 60th min; ##: p<0.05 vs. mice treated with morphine at 60th
min and 90th min. Mice received the following treatment:
 Control mice: Sal, s.c. (09.00 h.) and aCSF, i.c.v. (09.45 h).
 Mice  treated  with  obestatin:  Sal,  s.c.  (09.00 h.)  and  obestatin,  i.c.v.
(09.45 h).
 Mice treated with morphine: Mor, s.c. (09.00 h) and injection aCSF i.c.v.
(09.45 h).
 Mice  treated  with  morphine  +  obestatin:  Mor,  s.c.  (09.00 h.)  and
obestatin, i.c.v.  (09.45 h).
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3.10 The effect of obestatin on analgesic tolerance to morphine
Morphine tolerant mice showed significant higher pain sensitivity on the 3rd and 5th
day of experiments compared to the 1st day of the same group [F (3,28)= 67,693, P<0,001] and
significant lower pain-related behavior compared control on the 1st and 3rd day, but not on
the  5th  day. Morphine  tolerant  mice  receiving  obestatin  displayed  significant  higher  pain
sensitivity on the 5th day compared the 1st day of the same group [F(3,28)= 8,693, P<0,001].
Obestatin diminished the analgesic tolerance to morphine on the 5th day in morphine tolerant
mice  receiving  obestatin  compared  with morphine  tolerant  mice  [F(3,28)= 8,693,  P<0,001].
Drug - time interactions (drug-time [F(3,28)=15,813, P<0,001]; time [F(3,28)=25,473, P<0,003];
drug [F(3,28)=62,100, P<0,003]) were significant (Figure 11). (Sidak post-hoc)
Figure 11.  Curves represent the  percentage  of analgesic  effect;  vertical  lines on the
curves denote S.E. M., *: p <0.05 vs. morphine tolerant mice and control mice on the 5th day;
#: p <0.05 vs.  morphine tolerant  mice receiving obestatin  on the 1st  day;  ##:  p<0.05 vs.
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morphine tolerant mice on the 3rd and 1st day; ###: p<0.05 vs. morphine tolerant mice on 1st
day.
Mice received the following treatment:
 Control mice: Twice daily injections of Sal, s.c. (09.00 and 16.00 h.) and
once daily injection aCSF, i.c.v. (09.45 h) for 4 consecutive days. On the
test day, mice given: Sal, s.c. (09.00 h) and aCSF, i.c.v. (09.45 h).
 Mice treated with obestatin: Twice daily injections of Sal, s.c. (09.00 and
16.00 h.)  and  once  daily  injection  obestatin,  i.c.v.  (09.45  h)  for  4
consecutive days.  On the test day, mice given: Sal, s.c. (09.00 h), and
obestatin, i.c.v. (09.45 h).
 Morphine tolerant mice: Twice daily injections of  Mor, s.c. (09.00 and
16.00 h) and once daily injection aCSF (09.45 h), i.c.v. for 4 consecutive
days. On the test day, mice given: Mor, s.c. (08.00 h), aCSF. i.c.v. (09.45
h and Sal, s.c., (9.55 h).
 Morphine tolerant mice + obestatin: Twice daily injections of  Mor, s.c.
(09.00 and 16.00 h.) and once daily injection obestatin (09.45 h), i.c.v.
for 3 consecutive days. On the test day, mice given: Mor, s.c. (08.00 h),
and obestatin, i.c.v. (09.45. h.).
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4 Discussion
In this Ph.D. thesis work the behavioral effects of obestatin and PACAP on analgesic 
actions of morphine and morphine withdrawal were examined in mice. 
4.1 The effects of PACAP and obestatin on morphine withdrawal
Up to this point, the behavioral effects on PACAP and obestatin on morphine-induced
behavioral changes has been a poorly examined research field and the present data might
provide a new orientation for neuropeptides research.
Chronic morphine  withdrawal  is  known to be anxiogenic in humans and,  using the
EPM,  was  proved  to  be  anxiogenic  in  rats  as  well  (Schulteis  et  al.,  1998;  Zhang  and
Schulteis, 2008). In contrast to rats, both naloxone-precipitated  (Hodgson et al., 2008), and
spontaneous  opioid  withdrawal  (Buckman  et  al.,  2009)  exhibited  reduced  anxiety-like
behaviors on EPM   in mice. This increased open arm time may be regarded as escape or
defensive behavior or decrease feeling of fear (Hodgson et al., 2008).  Moreover, ERK 1/2
inhibitors  can  block  the  increased  open  arm-time  after  morphine  withdrawal  on  EPM
(Hofford et al., 2009).In contrast to EPM results, naloxone-precipitated morphine withdrawal
caused a rise in plasma and brain corticosterone levels (Hodgson et al., 2008). It is known that
morphine treatment alone and naloxone precipitated morphine withdrawal increase the ERK
1/2 phosphyration in mice (Li et al., 2010; Park et al., 2012). In addition, according to in vitro
studies, obestatin can stimulate ERK1/2 phosphorylation (see references in section 1.2.6.). 
Morphine indirectly decreases the intracellular level of cAMP due to inhibition of the
enzyme adenylate cyclase (Beitner et al., 1989; Kuriyama et al., 1978), but PACAP increases
the activity of adenylate cyclase, thus increasing the intracellular level of cAMP (Absood et
al., 1992). In contrast to the acute morphine treatment, withdrawal from chronic morphine
significantly upregulates the mRNA level of adenylate cyclase in the nucleus raphe magnus,
which causes an increase in cAMP level and hyperalgesia  (Bie et al., 2005). PACAP alone
caused hyperthermia in a dose dependent manner in rat  (Pataki et al., 2000) with 1000 ng
induced the largest elevation in body temperature. The hyperthermic effect of PACAP may be
mediated via a cyclooxygenase-involved pathway, and it suggests that PACAP may play an
important role in thermoregulation (Pataki et al., 2003). Morphine was able to induce either
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hyperthermia (through DOR and KOR opioid receptors)  or hypothermia (through l-opioid
receptors)  depending  on  the  dose  administrated,  but  naloxone-  precipitated  morphine
withdrawal evoked hypothermia  (Wang et al., 2008). In our study, we found that naloxone
induced hypothermia in mice treated with morphine was decreased by PACAP (Figure 3). 
Naloxone (0.2 mg/kg, s.c.) administration in mice treated with morphine significantly
increased  the  %OAT compared  to  the  control  mice  and the  mice  treated  with  morphine.
Moreover, naloxone significantly increased the %OAE compared with control mice and mice
received 0.1 mg/kg naloxone (Figure 4).  We also examined the effect of chronic PACAP
administration  on  naloxone  induced  morphine  withdrawal  behavior  using  EPM.  In  other
experiments, acute administration of PACAP at dose dependent manner influenced morphine-
induced locomotion: at lower doses (0.03 and 0.3 μg) increased, at higher dose inhibited (1
μg) morphine-induced locomotion (Marquez et al., 2009). According to another study, single
i.c.v. doses of 500 ng and 1 μg PACAP had locomotor stimulating effect in open field test, 30
min post-treatment in rat (Adamik and Telegdy, 2004). Therefore, in our experiments 30 min
after last PACAP injection (500 ng) the EPM test was started. After naloxone-precipitated
withdrawal,  PACAP  had  no  significant  effect  on  the  total  motor  activity  compared  to
morphine  withdrawal  mice  (Figure 6).  A  recent  study  suggested  that  chronic  stress
(footshock, forced swim, oscillation stress, etc.) increases PACAP mRNA expression in the
bed nucleus of the stria terminalis and PACAP is anxiogenic (Hammack et al.,  2009). We
could not confirm these results; PACAP alone increased the open arm time/ total time rate and
had no effect on total activity. Chronic PACAP treatment did not influence significantly the
open  arm  time/  total  time  rate  in  mice  undergoing  naloxone-precipitated  morphine
withdrawal.  These  results  allude  to  anxiolytic  effect  of  PACAP, but  differences  were  not
significant compared to aCSF treated control mice (P < 0.0614). Jump latency is an accepted
method to report the somatic signs of withdrawal (Babarczy et al., 1996; Miller et al., 1983).
Mice chronically treated with PACAP and morphine jumped off the platform earlier than mice
treated with morphine after withdrawal. Thus, PACAP enhanced this aversive effect of opioid
withdrawal (Figure 2). A previous study carried out in our laboratory showed a similar result
using morphine pellet implantation (Mácsai et al., 2002). Although withdrawal jumping is a
somatic  withdrawal  symptom in mice  and rats,  perhaps  this  is  a  similar  escape  behavior,
which  we  experienced  on  EPM  tests.  PACAP can inhibit spinal dynorphin release; and
PACAP6-38, a specific PAC1 receptor inhibitor, reverses this effect in rat (Liu et al., 2011).
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PACAP may exert its aversive effects on morphine-induced behavioral changes via mediation
of dynorphin release.
To our knowledge, there are no in vivo studies which examined the effects of obestatin
on morphine withdrawal in rodents. After chronic morphine treatment naloxone significantly
increased the %OAT and %OAE compared to control mice and mice treated with morphine in
the EPM (Figure 7). Our result supports the previous findings described by (Hodgson et al.,
2008).  The  same  experimental  protocol  was  used  in  the  OF test.  Mice  undergoing  mild
withdrawal  spent  significantly  more  time  and travelled  significantly  more  distance  in  the
center of the open field compared to the control mice and mice treated with morphine (Figure
9).  To our knowledge this  is the first  study which has confirmed this  effect  of naloxone-
precipitated mild morphine withdrawal in the open field test in mice. In line with literature,
naloxone alone did not alter the behavior of mice in our experiments (Hodgson et al., 2008;
Ribeiro et al., 1998). We injected obestatin obestatin 15 minutes prior to test in all experiment
due to our dose-response data and rapid degredation of obestatin (Pan et al., 2006). Obestatin
showed maximal  levels of ERK1/2 phosphorylation after 15 min of obestatin treatment in
vitro (Pazos et al., 2009).  In accordance with literature (Carlini et al., 2007), obestatin alone
had no effect on total activity compared control mice (Figure 8). Morphine withdrawal mice
receiving obestatin also showed no significant changes in total activity compared to morphine
withdrawal  mice  (Figure 8).  Chronic administration  of obestatin  alone had no significant
effect on EPM (Figure 7) and OF parameters (Figure 9), so we cannot support the results of
mentioned study in which obestatin caused a significant increase in the time spent in open arm
in rats  (Carlini et al., 2007).  This contradiction alludes to the species-dependent impact of
obestatin, although the amino acid-sequence of rat and mouse obestatin is completely same.
Obestatin displayed an inhibitory effect on %OAT in EPM (Figure 7) and the time spent and
ambulation distance in the center of the OF undergoing withdrawal (Figure 9). Although, our
result was not significant in the EPM tests (P < 0.086), it followed the same tendency that we
have recorded in the open field test after naloxone treatment.  
4.2 The effects of obestatin on the acute and chronic analgesic actions of morphine
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A previous study done by our research group demonstrated that PACAP diminished the
acute analgesic effect of morphine and enhanced the analgesic tolerance to morphine (Mácsai
et al. 2002). Due to these results, in this Ph.D. thesis work the effects of PACAP on analgesic
actions of morphine were not examined.
The reduction of analgesic effect of the single injection of morphine (Figure 10) and the
analgesic  tolerance  to morphine  (Figure 11) were confirmed using tail-flick assay. In our
experiments, obestatin alone had no significant analgesic effect. In tail-flick we also recorded
that obestatin significantly prolonged the analgesic effect of acute morphine 90 and 120 min
after morphine treatment (Figure 10) and prevented the analgesic tolerance to morphine in the
fifth day of chronic morphine treatment (Figure 11).
 A recently published study claimed that i.c.v. injection of ghrelin (0.1, 1, 10 and 100
nmol/L)  produced  inhibition  of  systemic  morphine  (6  mg/kg,  i.p.)  analgesia  in  the  tail
withdrawal  test  in  mice.  Furthermore,  [D-Lys3]-GHRP-6 injected  5  min  before  morphine
failed to block the analgesic effect of morphine. In addition, this action of ghrelin was not
blocked by pretreatment of i.c.v. injection of [D-Lys3]-GHRP-6. These results suggest that the
anti-opioid effect of ghrelin do not interact with GHS-R1a (Zeng et al., 2013). Taken together,
ghrelin  and obestatin  might  exert  their  effects  on morphine-induced analgesia  in different
pathways.
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5 Summary
In summary, the effects of two neuropeptides, PACAP and obestatin were examined on
morphine-induced behavioral changes in mice.
PACAP had no effect on EPM during naloxone-precipitated mild morphine withdrawal
and shortened withdrawal jump latency induced by naloxone in mice treated with morphine.
However, PACAP blunted the hypothermia induced by morphine withdrawal, but this positive
effect of PACAP presented only 15 minutes after withdrawal. 
Obestatin reversed the effects of mild morphine withdrawal on EPM on OF in mice.
Interestingly, obestatin enhanced the  analgesic effect of acute morphine and prevented the
analgesic tolerance to morphine in tail-flick test. The underlying mechanisms of these effects
of obestatin remained unclear; probably obestatin exerts its behavioral effects via ERK 1/2
activation and/or via GHSR-1a receptor.
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